Bactericidal/permeability-increasing protein in lacrimal gland and in tears of healthy subjects

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 244, Issue 2, 2006, Pages 143-148

  Peuravuori, Heikki ^a   Aho, Valtteri V ^a   Aho, Heikki J ^a   Collan, Yrjö ^a   Saari, K Matti ^a  

^a UNIVERSITY OF TURKU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERICIDAL PERMEABILITY INCREASING PROTEIN;

ADULT; ANTIBACTERIAL ACTIVITY; ARTICLE; AUTOPSY; CONJUNCTIVA; CONTROLLED STUDY; EPITHELIUM CELL; FEMALE; FLOW RATE; FLUOROIMMUNOASSAY; HUMAN; HUMAN EXPERIMENT; IMMUNOHISTOCHEMISTRY; LACRIMAL FLUID; LACRIMAL GLAND FUNCTION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; WESTERN BLOTTING;

ADULT; ANTIMICROBIAL CATIONIC PEPTIDES; BLOOD PROTEINS; BLOTTING, WESTERN; CONJUNCTIVA; EYE PROTEINS; FEMALE; FLUOROIMMUNOASSAY; HUMANS; IMMUNOENZYME TECHNIQUES; LACRIMAL APPARATUS; MALE; MEMBRANE PROTEINS; TEARS;

EID: 33644516250     PISSN: 0721832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00417-005-0062-z     Document Type: Article

References (28)

1. Abbott RL, Zegans M, Kremer PA (2004) Bacterial corneal ulcers. In: Tasman W, Jaeger EA (eds) Duane's clinical ophthalmology, vol. 4, 18. Lippincott Williams & Williams, pp 1-29
2. Aho HJ, Saari KM, Kallajoki M, Nevalainen TJ (1996) Synthesis of group II phospholipase A2 and lysozyme in lacrimal glands. Invest Ophthalmol Vis Sci 37:1826-1832
3. Aho VV, Nevalainen TJ, Paavilainen V, Saari KM (2002) Group II phospholipase A2 content of tears in patients with senile cataract and primary open-angle glaucoma. Eur J Ophthalmol 12:40-43
4. Aho VV, Nevalainen TJ, Saari KM (2002) Group IIA phospholipase A2 content of tears in basal, nonstimulated and reflex tears. Curr Eye Res 24:224-227
5. Aho VV, Nevalainen TJ, Saari KM (2002) Group IIA phospholipase A2 content of tears in patients with keratoconjunctivitis sicca. Graefe's Arch Clin Exp Ophthalmol 240:521-523
6. Aho VV, Paavilainen V, Nevalainen TJ, Peuravuori H, Saari KM (2003) Diurnal variation in group IIA phospholipase A2 content in tears of contact lens wearers and normal controls. Graefe's Arch Clin Exp Ophthalmol 241:85-88
7. Calafat J, Janssen H, Knol EF, Malm J, Egesten A (2000) The bactericidal/ permeability increasing protein (BPI) is membrane-associated in azurophil granules of human neutrophils, and relocation occurs upon cellular activation. Acta Pathol Microbiol Immunol Scand 108:201-208
8. Canny G, Levy O, Furuta GT, Narravula-Alipati S, Sisson RB, Serhan CN, Colgan SP (2002) Lipid mediator-induced expression of bactericidal/ permeability-increasing protein (BPI) in human mucosal epithelia. Proc Natl Acad Sci U S A 99:3902-3907
9. Elsbach P, Weiss J (1998) Role of the bactericidal/ permeability-increasing protein in host defence. Curr Opin Immunol 10:45-49
10. Fleming A (1922) On a remarkable bacteriolytic element found in tissues and secretions. Proc R Soc Ser B 93:306-317
11. Haynes RJ, Tighe PJ, Harminder SD (1999) Antimicrobial defensin peptides of the human ocular surface. Br J Ophthalmol 83:737-741
12. Häggblom J-O, Jokilammi-Siltanen AB, Peuravuori H, Nevalainen TJ (1996) Time-resolved fluoroimmunoassay for bactericidal/ permeability-increasing protein. Mediat Inflamm 5:47-50
13. Kuizenza A, van Haeringen NJ, Kijlstra A (1991) SDS-Minigel electrophoresis of human tears. Invest Ophthalmol Vis Sci 32:381-386
14. Levin M, Quint PA, Goldstein B, Barton P, Bradley JS, Shemie SD, Yeh T, Kim SS, Cafaro DP, Scannon PJ, Giroir BP (2000) Recombinant bactericidal/ permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: A randomised trial. rBPI21 Meningococcal Sepsis Study Group. Lancet 356:961-967
15. Levy O (2000) Antimicrobial proteins and peptides of blood: Templates for novel antimicrobial agents. Blood 96:2664-2672
16. Levy O (2002) Therapeutic potential of the bactericidal/ permeability-increasing protein. Expert Opin Invest Drugs 11:159-167
17. Masson PL, Heremans JF, Dive C (1966) An iron binding protein common to many external secretions. Clin Chim Acta 14:735
18. McClellan BH, Whitney CR, Newman LP, Allansmith MR (1973) Immunoglobulins in tears. Am J Ophthalmol 76:89-101
19. Milder B (1981) The lacrimal apparatus. In: Moses RA (ed) Adler's physiology of the eye, clinical application, 7th edn. CV Mosby Company, St Louis, pp 16-37
20. Nevalainen TJ, Aho HJ, Peuravuori H (1994) Secretion of group 2 phospholipase A2 by lacrimal glands. Investig Ophthalmol Vis Sci 32:417-421
21. Nupponen I, Turunen R, Nevalainen T, Peuravuori H, Pohjavuori M, Repo H, Andersson S (2002) Extracellular release of bactericidal/ permeability-increasing protein in newborn infants. Pediatr Res 51:670-674
22. Paulsen FP, Pufe T, Schaudig U, Held-Feindt J, Lehmann J, Schröder JM, Tillmann BN (2001) Detection of natural peptide antibiotics in human nasolacrimal ducts. Invest Ophthalmol Vis Sci 42:2157-2163
23. Qu X-D, Lehrer RJ (1998) Secretory phospholipase A2 is the principal bactericide for staphylococci and other Gram-positive bacteria in human tears. Infect Immun 66:2791-2797
24. Rauniyar RK, Suzuma K, King AL, Aiello LP, King GL (2002) Differential effects of bactericidal/permeability-increasing protein (BPI) analogues on retinal neovascularization and retinal pericyte growth. Invest Ophthalmol Vis Sci 43:503-509
25. Rintala E, Peuravuori H, Pulkki K, Voipio-Pulkki L-M, Nevalainen T (2000) Bactericidal/permeability-increasing protein (BPI) in sepsis correlates with the severity of sepsis and the outcome. Intensive Care Med 26:1248-1251
26. Saari KM, Aho VV, Paavilainen V, Nevalainen TJ (2001) Group II phospholipase A2 content of tears in normal subjects. Invest Ophthalmol Vis Sci 42:318-320
27. Saari KM, Aine E, Posz A, Klockars M (1983) Lysozyme content of tears in normal subjects and in patients with external eye infections. Graefe's Arch Clin Exp Ophthalmol 221:86-88
28. Weiss J, Elsbach P, Shu C, Castillo J, Grinna L, Horwitz A, Theofan G (1992) Human bactericidal/permeability-increasing protein and a recombinant NH2-terminal fragment cause killing of serum-resistant gram-negative bacteria in whole blood and inhibit tumor necrosis factor release induced by the bacteria. J Clin Invest 90:1122-1130